MANNKIND CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MNKD in the last 30 days.
See all $MNKD insider activity →MannKind (MNKD) shares rose 5% after FDA approved Afrezza for diabetes treatment in children aged 6+. The approval follows Phase 3 trial data showing Afrezza's noninferiority to injections in HbA1c changes, with higher patient satisfaction and less weight gain. Afrezza uses Technosphere tech for rapid insulin delivery via inhalation.
The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.
MannKind (MNKD) filed a prospectus supplement for the resale of up to 12.85 million shares of common stock by existing selling stockholders, including 2.41 million shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from the resale but will cover registration expenses. The shares were last traded at $4.26 on August 20, 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning MNKD (MANNKIND CORP). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MNKD coverage spans corporate actions, regulation and earnings.
Regulatory approval unlocks new pediatric market, boosting revenue potential.
Collaboration could add milestone payments and broaden MannKind's pipeline.
The resale registration does not provide proceeds to MannKind and may increase float, potentially diluting existing shareholders.
Potential dilution and capital raise pending; market may price in future equity offering.
Post-approval financing supports commercialization readiness while settling an FDA-triggered milestone obligation.
alphai scores every news story that mentions MNKD with an AI model for sentiment and relevance, and aggregates insider trades from MANNKIND CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
MannKind (MNKD) shares rose 5% after FDA approved Afrezza for diabetes treatment in children aged 6+. The approval follows Phase 3 trial data showing Afrezza's noninferiority to injections in HbA1c changes, with higher patient satisfaction and less weight gain. Afrezza uses Technosphere tech for rapid insulin delivery via inhalation.
2 min readThe FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.
2 min readMannKind (MNKD) filed a prospectus supplement for the resale of up to 12.85 million shares of common stock by existing selling stockholders, including 2.41 million shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from the resale but will cover registration expenses. The shares were last traded at $4.26 on August 20, 2026.
2 min readMannKind Corp. (MNKD) filed a prospectus supplement and a legal opinion from Cooley LLP for a common stock offering under its shelf registration on Form S-3. The Form 8-K filing includes the opinion, supporting the planned sale of common stock. The SEC filing was made on August 21, 2026.
1 min readThree Connecticut firms outlined different financing paths. New Silver said it acquired Mayflower Venture Partners to expand lending in New England, with deal terms undisclosed. American Battery Materials filed to raise about $16.3M for Utah lithium and magnesium exploration, targeting production in 2029. MannKind raised $50M after FDA approval of Furoscix ReadyFlow, funding a $45M milestone payment and aiming for U.S. sales by end-August.
6 min readMannKind (MNKD) shares rose 5.1% after the company reported Q2 2026 revenue of $109.37 million, up from $76.53 million a year earlier, but a net loss of $19.03 million versus a small net profit. MannKind also released positive Phase 1b inhaled nintedanib DPI safety data for idiopathic pulmonary fibrosis.
6 min readMANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema
4 min readMannKind (Nasdaq: MNKD) reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis. In 27 patients, it met safety and tolerability goals with no serious adverse events, no bronchospasm or diarrhea, and no discontinuations. Phase 2 INFLO-2 is enrolling about 210 patients.
3 min readMannKind Corporation (NASDAQ: MNKD) said it will release Q2 2026 financial results after the market close on Aug. 5, 2026. A conference call is scheduled for 4:30 p.m. ET with a webcast and replay on the company’s investor site. The article also notes a Breakthrough T1D grant supporting the INHALE-1ST Afrezza study in pediatric type 1 diabetes.
4 min readMannKind Corp. said it raised $50 million from institutional investors after the FDA approved Furoscix ReadyFlow, an injectable for adults with heart failure or chronic kidney disease with fluid overload. Proceeds include a $45 million milestone payment tied to MannKind’s 2025 scPharmaceuticals acquisition. MannKind expects US availability by end-August.
3 min read
